Related Experiment Video
Updated: Jul 3, 2026

Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis
Hua-Song Zeng1, Xiao-Yan Xiong, Yan-Dan Wei
1Department of Allergy, Immunology and Rheumatology, Guangzhou Children's Hospital, Guangzhou 510120, China. huasongz@gmail.com
Insights
Macrophage activation syndrome (MAS) is a severe complication of systemic-onset juvenile idiopathic arthritis (SoJIA). Early recognition and treatment of MAS in children are crucial for reducing mortality rates.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Hematology
Background:
- Macrophage activation syndrome (MAS) is a life-threatening condition associated with chronic rheumatic diseases, particularly systemic-onset juvenile idiopathic arthritis (SoJIA) in children.
- MAS presents with diverse clinical and laboratory findings, often lacking specific characteristics, making early diagnosis challenging.
Purpose of the Study:
- To analyze the clinical and laboratory features of SoJIA patients diagnosed with MAS.
- To identify key characteristics that aid in the early recognition and management of MAS in pediatric patients.
Main Methods:
- Retrospective analysis of clinical and laboratory data from 13 SoJIA patients with MAS.
- Data collected from January 2003 to October 2007.
Main Results:
- The study included 13 patients (9 boys, 4 girls) aged 5 months to 12 years.
- Common manifestations included persistent fever, anemia, arthritis, hepatosplenomegaly, lymphadenopathy, liver dysfunction, abnormal lipid metabolism, and bone marrow hemophagocytosis.
- Severe complications such as acute respiratory distress syndrome and multi-organ failure occurred, with a mortality rate of 23% (3 out of 13 patients).
- Perforin A91V gene analysis in 6 patients showed normal results.
- Glucocorticoids, immunosuppressive therapy, and plasmapheresis (in one severe case) demonstrated effectiveness.
Conclusions:
- MAS is a critical complication of juvenile idiopathic arthritis (JIA), especially the systemic-onset form.
- Prompt diagnosis and timely intervention are essential to improve outcomes and reduce mortality in pediatric MAS patients.
Background:
Macrophage activation syndrome (MAS) is a severe, potentially life-threatening condition induced by chronic rheumatic diseases, especially systemic-onset juvenile idiopathic arthritis (SoJIA) in childhood. This study aimed to analyze the clinical and laboratory characteristics of systemic-onset juvenile idiopathic arthritis (SoJIA) with macrophage activation syndrome (MAS) in 13 patients.
Methods:
Clinical and laboratory data of 13 SoJIA patients with MAS treated in our hospital from January 2003 to October 2007 were analyzed.
Results:
In the 13 patients, 9 were boys and 4 girls aged from 5 months to 12 years. Clinical manifestations were of no typical characteristics including persistent fever, anemia, arthritis, hepatosplenomegaly, lymph-adenopathy, dysfunction of the liver, abnormal fat metabolism, and hemophagocytic cells in the bone marrow. Two patients experienced acute respiratory distress syndrome, two had mutiorgan failure, and three died. The perforin A91V (NCBI:SNP rs35947132) gene in 6 patients was normal. Glucocorticoid and immunoimpressive therapy were effective in all patients and plasmapheresis used in one severe patient was also effective.
Conclusions:
MAS is a serious complication of JIA, especially systemic-onset juvenile idiopathic arthritis. It is essentially important to recognize and treat MAS earlier in order to lower the mortality.
Related Concept Videos
The JAK-STAT Signaling Pathway
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Hypersensitivity Reactions: Immune-Complex Reactions